Your browser doesn't support javascript.
loading
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.
Ju, Young Seok; Martincorena, Inigo; Gerstung, Moritz; Petljak, Mia; Alexandrov, Ludmil B; Rahbari, Raheleh; Wedge, David C; Davies, Helen R; Ramakrishna, Manasa; Fullam, Anthony; Martin, Sancha; Alder, Christopher; Patel, Nikita; Gamble, Steve; O'Meara, Sarah; Giri, Dilip D; Sauer, Torril; Pinder, Sarah E; Purdie, Colin A; Borg, Åke; Stunnenberg, Henk; van de Vijver, Marc; Tan, Benita K T; Caldas, Carlos; Tutt, Andrew; Ueno, Naoto T; van 't Veer, Laura J; Martens, John W M; Sotiriou, Christos; Knappskog, Stian; Span, Paul N; Lakhani, Sunil R; Eyfjörd, Jórunn Erla; Børresen-Dale, Anne-Lise; Richardson, Andrea; Thompson, Alastair M; Viari, Alain; Hurles, Matthew E; Nik-Zainal, Serena; Campbell, Peter J; Stratton, Michael R.
Affiliation
  • Ju YS; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Martincorena I; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
  • Gerstung M; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Petljak M; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Alexandrov LB; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton CB10 1SD, UK.
  • Rahbari R; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Wedge DC; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Davies HR; Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA.
  • Ramakrishna M; Genomic Mutation and Genetic Disease, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Fullam A; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Martin S; Oxford Big Data Institute and Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, Oxford, UK.
  • Alder C; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Patel N; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Gamble S; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • O'Meara S; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Giri DD; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Sauer T; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Pinder SE; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Purdie CA; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Borg Å; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
  • Stunnenberg H; Institute of Clinical Medicine, Campus at Akershus University Hospital, University of Oslo, Lørenskog, Norway.
  • van de Vijver M; King's Health Partners Cancer Biobank, Guy's Hospital, King's College London School of Medicine, London, UK.
  • Tan BK; Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK.
  • Caldas C; BioCare, Strategic Cancer Research Program, Lund, Sweden.
  • Tutt A; CREATE Health, Strategic Centre for Translational Cancer Research, Lund, Sweden.
  • Ueno NT; Department of Oncology and Pathology, Lund University Cancer Center, Lund, Sweden.
  • van 't Veer LJ; Radboud University Medical Center, Nijmegen, The Netherlands.
  • Martens JW; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
  • Sotiriou C; SingHealth Duke-NUS Breast Centre, Division of Surgical Oncology, National Cancer Centre Singapore, Department of General Surgery, Singapore General Hospital, Singapore.
  • Knappskog S; Cancer Research UK (CRUK) Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Span PN; Breast Cancer Now Research Unit, King's College London, London SE1 9RT, UK.
  • Lakhani SR; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London SW3 6JB, UK.
  • Eyfjörd JE; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Børresen-Dale AL; Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.
  • Richardson A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Thompson AM; Institut Jules Bordet, Brussels, Belgium.
  • Viari A; Section of Oncology, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Hurles ME; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
  • Nik-Zainal S; Department of Radiation Oncology and Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Campbell PJ; University of Queensland, School of Medicine, Brisbane, Australia.
  • Stratton MR; Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Nature ; 543(7647): 714-718, 2017 03 30.
Article in En | MEDLINE | ID: mdl-28329761
ABSTRACT
Somatic cells acquire mutations throughout the course of an individual's life. Mutations occurring early in embryogenesis are often present in a substantial proportion of, but not all, cells in postnatal humans and thus have particular characteristics and effects. Depending on their location in the genome and the proportion of cells they are present in, these mosaic mutations can cause a wide range of genetic disease syndromes and predispose carriers to cancer. They have a high chance of being transmitted to offspring as de novo germline mutations and, in principle, can provide insights into early human embryonic cell lineages and their contributions to adult tissues. Although it is known that gross chromosomal abnormalities are remarkably common in early human embryos, our understanding of early embryonic somatic mutations is very limited. Here we use whole-genome sequences of normal blood from 241 adults to identify 163 early embryonic mutations. We estimate that approximately three base substitution mutations occur per cell per cell-doubling event in early human embryogenesis and these are mainly attributable to two known mutational signatures. We used the mutations to reconstruct developmental lineages of adult cells and demonstrate that the two daughter cells of many early embryonic cell-doubling events contribute asymmetrically to adult blood at an approximately 21 ratio. This study therefore provides insights into the mutation rates, mutational processes and developmental outcomes of cell dynamics that operate during early human embryogenesis.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Embryonic Development / Embryo, Mammalian / Mutation Type of study: Prognostic_studies Limits: Adult / Humans Language: En Journal: Nature Year: 2017 Document type: Article Affiliation country: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Embryonic Development / Embryo, Mammalian / Mutation Type of study: Prognostic_studies Limits: Adult / Humans Language: En Journal: Nature Year: 2017 Document type: Article Affiliation country: Reino Unido
...